Take the Tufts CSDD Global Survey on the Impact of DCTs on Sponsor-CRO Collaborations

Why constant communication and transparency are paramount to successful partnerships between pharmaceutical companies and CROs

The era of big pharma as product-first companies must end, as services become the larger priority.

To rebuild trust, companies should focus on transparent, neutral content incorporating medical expertise and regularly seeking HCP feedback.

Agency will be reorganizing field force and compliance functions.

EU proposal focuses on a subset of underserved rare diseases—exploring the gaps in those conditions for which there is no approved treatment option.

Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.